A detailed history of Jacobs Levy Equity Management, Inc transactions in Replimune Group, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 39,521 shares of REPL stock, worth $494,012. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,521
Previous 83,674 52.77%
Holding current value
$494,012
Previous $753,000 42.5%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.09 - $11.23 $357,197 - $495,838
-44,153 Reduced 52.77%
39,521 $433,000
Q2 2024

Aug 14, 2024

SELL
$5.01 - $9.46 $248,100 - $468,468
-49,521 Reduced 37.18%
83,674 $753,000
Q1 2024

May 15, 2024

BUY
$6.87 - $9.31 $915,049 - $1.24 Million
133,195 New
133,195 $1.09 Million

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $616M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.